Tekmira Provides Update on Collaboration With U.S. Government's TMT Program
06 août 2012 06h55 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 6, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
17 juil. 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, July 17, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Tekmira's LNP Technology Enables Alnylam's Positive ALN-TTR02 Clinical Data
16 juil. 2012 11h12 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, July 16, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira's LNP Technology Enables ALN-VSP Clinical Data
04 juin 2012 10h36 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, June 4, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
24 mai 2012 18h13 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 24, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided a...
Tekmira Provides Corporate Update and Announces First Quarter 2012 Results
15 mai 2012 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 15, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira's LNP Technology Enables Alnylam's ALN-TTR01 Clinical Data
10 mai 2012 09h56 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 10, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter 2012 Results
09 mai 2012 16h47 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 9, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it...
Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data
20 avr. 2012 10h51 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 20, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Provides Corporate Update and Announces 2011 Results
27 mars 2012 16h01 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 27, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its...